in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Aurobindo receives FDA approval for generic Cymbalta
December 13, 2013 | Natasha Alperowicz
Aurobindo Pharma (Hyderabad) said today that it has received final approval from the FDA to manufacture and market duloxetine hydrochloride delayed-release capsules 20, 30 and 60 mg. The product is the generic equivalent of Eli Lilly’s Cymbalta drug, used to treat major depressive disorders. The market size in the US for this product last year was estimated by IMS to be in the region of $5.4-5.5 billion. Aurobindo is the third Indian company to announce FDA’s approval for the product. On Thursday Sun Pharmaceutical Industries (Mumbai) and Lupin...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee